(Bloomberg) — Swedish Orphan Biovitrum AB has agreed to buy bio-pharmaceutical company CTI BioPharma Corp. in a deal valued at $1.7 billion.
Most Read from Bloomberg
Sobi will acquire all the outstanding stock of CTI for $9.10 per share, the Stockholm-based company said a statement. The offer equals a premium of 88.8% from the last closing price.
The deal is expected to accelerate Sobi’s revenue growth and to improve margins by adding a commercial-stage asset in the US. CTI is primarily focused on blood related cancers and rare diseases.
“The acquisition of CTI is the latest in a series of transformative transactions Sobi has conducted to build its leading rare haematology franchise,” Sobi Chief Executive Officer Guido Oelkers said.
The transaction will initially be funded with debt financing from Bank of America Corp. and Danske Bank A/S. Sobi said that as much as half of the purchase consideration will be refinanced through an issuance of new ordinary shares of Sobi after the closing of the acquisition.
The “transaction terms looks reasonable,” Handelsbanken analyst Mattias Haggblom said in a client note. “Based on Bloomberg consensus, CTI Biopharma was expected to become profitable in 2024 and there are certainly going to be synergies for Sobi to extract to accelerate that profitability.”
Sobi’s main shareholder Investor AB — controlled by the powerful Wallenberg family — has agreed to subscribe for its pro-rata share of the rights issue, corresponding to about 34.7% of the shares to be issued.
CTI board unanimously approved the transaction and recommended that the shareholders tender their shares. The deal is expected to close in the third quarter of this year.
Story continues
Read More: Sobi to Buy CTI BioPharma for $9.10/Share in Cash: M&A Snapshot
—With assistance from Jonas Cho Walsgard.
Most Read from Bloomberg Businessweek
©2023 Bloomberg L.P.